VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
PSNLPersonalis, Inc.
$10.54$936M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist

PSNL logoPersonalis, Inc.(PSNL)Earnings, Financials & Key Ratios

PSNL•NASDAQ
Price updated Jun 19, 2026
SectorHealthcareIndustryDiagnostics & ResearchSub-IndustryMolecular and Genetic Diagnostics
AboutPersonalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.; and Moores Cancer Center. Personalis, Inc. was incorporated in 2011 and is headquartered in Menlo Park, California.Show more
  • Revenue$0-100.0%
  • EBITDA-$78M-36.1%
  • Net Income-$81M
  • EPS (Diluted)-0.91+33.6%
  • ROE-35.02%+28.4%

PSNL Key Insights

Personalis, Inc. (PSNL) fundamental analysis — strengths, weaknesses & financial health based on data analysis

✓Strengths

  • ✓Momentum leader: RS Rating 87 (top 13%)

✗Weaknesses

  • ✗Profits declining 14.5% over 5 years
  • ✗Shares diluted 50.6% in last year
  • ✗Low asset turnover indicates capital-intensive operations

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Get notified when PSNL posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

PSNL Price & Volume

Personalis, Inc. (PSNL) stock price & volume — 10-year historical chart

Loading chart...

PSNL Growth Metrics

Personalis, Inc. (PSNL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR

Revenue CAGR

10 Years-
5 Years-
3 Years-
TTM-24.71%

Profit CAGR

10 Years-
5 Years-
3 Years-
TTM-13.66%

EPS CAGR

10 Years-
5 Years-
3 Years-
TTM20.93%

Return on Capital

10 Years-36.03%
5 Years-35.19%
3 Years-38.67%
Last Year-33%

PSNL Recent Earnings

Personalis, Inc. (PSNL) EPS & revenue vs analyst estimates — last 4 quarters

Full history →
●Beat EPS 10/12 qtrs (83%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
May 7, 2026
Metric
Actual
Est
EPS
$0.29-26.1%
$0.23
Rev
$15M+6.8%
$14M
Q1 2026
Feb 26, 2026
Metric
Actual
Est
EPS
$0.26+16.1%
$0.31
Rev
$17M+1.7%
$17M
Q4 2025
Nov 4, 2025
Metric
Actual
Est
EPS
$0.24+14.3%
$0.28
Rev
$14M-14.9%
$17M
Q3 2025
Aug 5, 2025
Metric
Actual
Est
EPS
$0.23+8.0%
$0.25
Rev
$17M-14.5%
$20M
QuarterDateEPS (Act vs Est)Revenue (Act vs Est)
Q2 2026LatestMay 7, 2026
$0.29vs $0.23-26.1%
$15Mvs $14M+6.8%
Q1 2026Feb 26, 2026
$0.26vs $0.31+16.1%
$17Mvs $17M+1.7%
Q4 2025Nov 4, 2025
$0.24vs $0.28+14.3%
$14Mvs $17M-14.9%
Q3 2025Aug 5, 2025
$0.23vs $0.25+8.0%
$17Mvs $20M-14.5%
Based on last 12 quarters of dataView full earnings history →

PSNL Peer Comparison

Personalis, Inc. (PSNL) competitors in Molecular and Genetic Diagnostics — business model, growth, and fundamentals comparison

Select Columns
Stock Universe
Valuation
Growth
Profitability
Financial Health
Dividends & Buybacks
Price Performance
Technical
Fundamentals ($)
Sector-Specific
Institutional Holdings
CompanyMarket CapStock PriceP/E Ratio (TTM)Revenue Growth 1YNet MarginReturn on Equity (ROE)FCF YieldDebt / Equity
NTRA logoNTRANatera, Inc.Direct Competitor33.14B231.41-152.2435.9%-9.05%-15.13%0.13
EXAS logoEXASExact Sciences CorporationDirect Competitor20.02B104.91-95.3717.69%-6.4%-8.66%1.05
GH logoGHGuardant Health, Inc.Direct Competitor17.47B131.78-39.6932.88%-40.1%
TWST logoTWSTTwist Bioscience CorporationDirect Competitor5.45B87.56-67.3520.32%-19.85%-17.46%0.29
ILMN logoILMNIllumina, Inc.Product Competitor24.6B161.9329.71-0.78%19.43%32.84%0.94
PACB logoPACBPacific Biosciences of California, Inc.Product Competitor434.84M1.40-0.773.89%-80.34%-488.45%141.98
CDNA logoCDNACareDx, IncProduct Competitor1.35B26.18-65.4513.79%-1.98%-2.61%0.06
VCYT logoVCYTVeracyte, Inc.Product Competitor4.28B53.6365.4016.01%16.25%6.86%0.03

Compare PSNL vs Peers

Personalis, Inc. (PSNL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs NTRA

Most directly comparable listed peer for PSNL.

Scale Benchmark

vs TMO

Larger-name benchmark to compare PSNL against a more recognizable public peer.

Peer Set

Compare Top 5

vs NTRA, EXAS, GH, TWST

PSNL Income Statement

Personalis, Inc. (PSNL) annual income statement — 10-year revenue, gross profit & net income history

10Y historyFree accessUpdated daily
MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Sales/Revenue
9.39M37.77M65.21M78.65M85.49M65.05M73.48M84.61M064.52M
Revenue Growth %
-302.15%72.62%20.61%8.7%-23.92%12.97%15.15%-100%-24.71%
Cost of Goods Sold
11.74M25.97M43.13M58.53M53.84M51.7M55.27M57.79M53.87M55.66M
COGS % of Revenue
124.94%68.75%66.14%74.43%62.97%79.48%75.22%68.3%--
Gross Profit
-2.34M▲ 0%
11.8M▲ 603.8%
22.08M▲ 87.0%
20.11M▼ 8.9%
31.66M▲ 57.4%
13.35M▼ 57.8%
18.21M▲ 36.4%
26.82M▲ 47.3%
-53.87M▼ 300.8%
8.85M▲ 0%
Gross Margin %
-24.94%31.25%33.86%25.57%37.03%20.52%24.78%31.7%-13.72%
Gross Profit Growth %
-603.84%87.04%-8.9%57.39%-57.83%36.39%47.33%-300.82%-
Operating Expenses
19.82M25.57M44.5M62.26M97.01M128.88M128.14M95.09M34.19M111.37M
OpEx % of Revenue
211.01%67.71%68.24%79.16%113.47%198.14%174.39%112.38%--
Selling, General & Admin
9.9M11.27M22.08M33.69M47.7M63.97M49.73M46.19M53.57M59.21M
SG&A % of Revenue
105.41%29.84%33.86%42.84%55.79%98.34%67.67%54.59%--
Research & Development
9.92M14.3M22.42M28.57M49.31M64.91M64.78M48.91M50.26M52.16M
R&D % of Revenue
105.6%37.87%34.38%36.32%57.68%99.79%88.15%57.8%--
Other Operating Expenses
0-33K000013.64M0-69.65M1K
Operating Income
-22.16M▲ 0%
-13.77M▲ 37.9%
-22.42M▼ 62.8%
-42.15M▼ 88.0%
-65.35M▼ 55.1%
-115.53M▼ 76.8%
-109.94M▲ 4.8%
-68.27M▲ 37.9%
-88.06M▼ 29.0%
-102.52M▲ 0%
Operating Margin %
-235.95%-36.45%-34.38%-53.59%-76.44%-177.61%-149.61%-80.68%--158.91%
Operating Income Growth %
-37.87%-62.8%-88%-55.06%-76.78%4.84%37.9%-28.99%-
EBITDA
-20.95M-10.7M-17.67M-36.39M-59.34M-107.1M-98.64M-57.33M-78.01M-92.69M
EBITDA Margin %
-223.01%-28.34%-27.1%-46.27%-69.41%-164.65%-134.24%-67.75%--143.68%
EBITDA Growth %
-48.9%-65.08%-105.93%-63.07%-80.49%7.9%41.88%-36.08%-64.37%
D&A (Non-Cash Add-back)
1.22M3.07M4.75M5.76M6.01M8.43M11.3M10.94M10.05M9.83M
EBIT
-22.29M-17.98M-23.94M-41.22M-65.03M-113.07M-108.1M-81.24M-81.04M-97.55M
Net Interest Income
-1.2M-1.6M487K947K183K2.19M5.79M5.49M6.95M7.08M
Interest Income
100K293K1.62M949K367K2.4M5.9M5.51M7.16M7.24M
Interest Expense
1.3M1.89M1.13M2K184K201K110K24K205K160K
Other Income/Expense
-1.43M-6.11M-2.66M923K141K2.26M1.72M-13M6.81M7M
Pretax Income
-23.59M▲ 0%
-19.88M▲ 15.7%
-25.07M▼ 26.1%
-41.22M▼ 64.4%
-65.21M▼ 58.2%
-113.28M▼ 73.7%
-108.21M▲ 4.5%
-81.27M▲ 24.9%
-81.25M▲ 0.0%
-95.52M▲ 0%
Pretax Margin %
-251.18%-52.63%-38.45%-52.41%-76.28%-174.14%-147.27%-96.04%--148.06%
Income Tax
5K7K9K57K14K40K83K18K21K30K
Effective Tax Rate %
-0.02%-0.04%-0.04%-0.14%-0.02%-0.04%-0.08%-0.02%-0.03%-0.03%
Net Income
-23.6M▲ 0%
-19.89M▲ 15.7%
-25.08M▼ 26.1%
-41.28M▼ 64.6%
-65.23M▼ 58.0%
-113.31M▼ 73.7%
-108.3M▲ 4.4%
-81.28M▲ 24.9%
-81.27M▲ 0.0%
-95.55M▲ 0%
Net Margin %
-251.23%-52.64%-38.47%-52.49%-76.29%-174.2%-147.38%-96.06%--148.11%
Net Income Growth %
-15.73%-26.14%-64.57%-58.01%-73.73%4.43%24.94%0.02%-13.66%
Net Income (Continuing)
-23.6M-19.89M-25.08M-41.28M-65.23M-113.31M-108.3M-81.28M-81.27M-95.55M
Discontinued Operations
0000000000
Minority Interest
0000000000
EPS (Diluted)
-1.08▲ 0%
-0.91▲ 15.7%
-1.39▼ 52.7%
-1.20▲ 13.7%
-1.49▼ 24.2%
-2.48▼ 66.4%
-2.25▲ 9.3%
-1.37▲ 39.1%
-0.91▲ 33.6%
-0.92▲ 0%
EPS Growth %
-15.74%-52.75%13.67%-24.17%-66.44%9.27%39.11%33.58%20.93%
EPS (Basic)
-1.08-0.91-1.39-1.20-1.49-2.48-2.25-1.37-0.91-
Diluted Shares Outstanding
21.75M21.75M18.01M34.37M43.89M45.7M48.18M59.25M89.24M104.19M
Basic Shares Outstanding
21.75M21.75M18.01M34.37M43.89M45.7M48.18M59.25M89.24M104.19M
Dividend Payout Ratio
----------

PSNL Balance Sheet

Personalis, Inc. (PSNL) balance sheet — assets, liabilities & shareholders' equity

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Total Current Assets
26.73M29.56M139.58M220.72M318.23M199.7M146.74M203.01M267.95M258.2M
Cash & Short-Term Investments
22.62M19.74M128.29M203.29M287.06M167.66M114.18M185.01M239.95M233.22M
Cash Only
22.62M19.74M55.05M68.53M105.58M89.13M56.98M91.42M124.25M73.59M
Short-Term Investments
0073.24M134.76M181.48M78.53M57.2M93.59M115.71M159.62M
Accounts Receivable
1.94M4.46M3.3M6.35M18.47M16.64M17.73M8.14M16.2M13.02M
Days Sales Outstanding
75.2743.0718.4729.4778.8593.3888.0735.11-75.75
Inventory
822K2.13M1.42M2.67M4.08M6.38M5.66M3.98M6.14M6.93M
Days Inventory Outstanding
25.5629.9912.0516.6827.6745.0737.3825.1141.6335.03
Other Current Assets
542K1.3M3.18M2.96M1.53M9.02M9.17M5.89M5.65M5.03M
Total Non-Current Assets
6.84M12.11M17.71M24.12M78.3M93M78.36M67.25M66.21M67.2M
Property, Plant & Equipment
6.34M11.45M15.95M22.11M73.47M88.42M75.22M64.73M59.93M63.4M
Fixed Asset Turnover
1.48x3.30x4.09x3.56x1.16x0.74x0.98x1.31x-1.04x
Goodwill
0000000000
Intangible Assets
0000000000
Long-Term Investments
0000000000
Other Non-Current Assets
495K659K1.76M2.02M4.83M4.59M3.14M2.53M6.28M3.8M
Total Assets
33.56M▲ 0%
41.67M▲ 24.2%
157.29M▲ 277.5%
244.84M▲ 55.7%
396.53M▲ 62.0%
292.7M▼ 26.2%
225.1M▼ 23.1%
270.27M▲ 20.1%
334.16M▲ 23.6%
325.39M▲ 0%
Asset Turnover
0.28x0.91x0.41x0.32x0.22x0.22x0.33x0.31x-0.22x
Asset Growth %
-24.15%277.47%55.66%61.95%-26.18%-23.1%20.07%23.64%83.38%
Total Current Liabilities
48.99M57.85M49.96M40.64M31.31M33.13M47.23M31.13M39.63M39.05M
Accounts Payable
4.04M6.57M7.34M8.3M9.22M12.85M14.92M6.4M12.99M12.68M
Days Payables Outstanding
125.4992.2762.151.7662.5290.7598.5340.488.0176.62
Short-Term Debt
17.51M5M001.81M2.22M1.65M1.67M00
Deferred Revenue (Current)
24.71M42.9M35.98M21.03M4.36M1.29M3.29M3.1M01.63M
Other Current Liabilities
718K43.18M4.39M8.45M11.19M9.55M19.62M10.86M26.64M26.37M
Current Ratio
0.55x0.51x2.79x5.43x10.16x6.03x3.11x6.52x6.76x6.61x
Quick Ratio
0.53x0.47x2.77x5.37x10.03x5.83x2.99x6.39x6.61x6.44x
Cash Conversion Cycle
-24.66-19.21-31.57-5.624447.726.9319.82-34.16
Total Non-Current Liabilities
77.18M90.21M639K9.26M54.91M41.43M48.42M36.19M33.35M31.59M
Long-Term Debt
292K683K00000031.87M31.02M
Capital Lease Obligations
00639K8.54M52.8M41.04M38.32M34.88M066.05M
Deferred Tax Liabilities
0000000000
Other Non-Current Liabilities
76.89M89.53M0720K2.12M389K10.1M1.3M1.48M562K
Total Liabilities
126.17M148.06M50.6M49.9M86.23M74.56M95.66M67.31M72.98M70.63M
Total Debt
17.51M5M2M10.99M58.33M48.65M47.73M44.25M31.87M31.02M
Net Debt
-5.11M-14.75M-53.05M-57.54M-47.25M-40.48M-9.26M-47.17M-92.38M-42.57M
Debt / Equity
--0.02x0.06x0.19x0.22x0.37x0.22x0.12x0.12x
Debt / EBITDA
----------0.33x
Net Debt / EBITDA
---------0.46x
Interest Coverage
-17.11x-9.50x-21.13x-20610.50x-353.41x-562.56x-982.75x-3385.08x-395.34x-609.71x
Total Equity
-92.6M▲ 0%
-106.39M▼ 14.9%
106.69M▲ 200.3%
194.94M▲ 82.7%
310.3M▲ 59.2%
218.14M▼ 29.7%
129.44M▼ 40.7%
202.96M▲ 56.8%
261.19M▲ 28.7%
254.76M▲ 0%
Equity Growth %
--14.89%200.28%82.72%59.17%-29.7%-40.66%56.79%28.69%124.32%
Book Value per Share
-4.26-4.895.925.677.074.772.693.432.932.45
Total Shareholders' Equity
-92.6M-106.39M106.69M194.94M310.3M218.14M129.44M202.96M261.19M254.76M
Common Stock
1K1K3K4K4K5K5K9K10K10K
Retained Earnings
-95.62M-115.5M-140.59M-181.87M-247.09M-360.41M-468.71M-549.99M-631.26M-661.29M
Treasury Stock
-3.02M-9.13M00000000
Accumulated OCI
-10K-15K-6K22K-166K-912K-222K-23K104K-70K
Minority Interest
0000000000

PSNL Cash Flow Statement

Personalis, Inc. (PSNL) cash flow — operating, investing & free cash flow history

MetricDec'17Dec'18Dec'19Dec'20Dec'21Dec'22Dec'23Dec'24Dec'25TTM
Cash from Operations
290K5.57M-18.07M-42.65M-70.83M-70.23M-56.26M-45.15M-74.95M-79.46M
Operating CF Margin %
3.09%14.75%-27.71%-54.23%-82.85%-107.97%-76.56%-53.36%--
Operating CF Growth %
-1821.38%-424.28%-136.06%-66.06%0.84%19.9%19.74%-65.99%-482.7%
Net Income
-23.6M-19.89M-25.08M-41.28M-65.23M-113.31M-108.3M-81.28M-81.27M-95.55M
Depreciation & Amortization
1.22M3.07M4.75M5.76M6.01M8.43M11.3M10.94M10.05M9.83M
Stock-Based Compensation
753K1.32M4.86M8.24M14.38M19.43M14.05M10.69M9.43M7.21M
Deferred Taxes
226K4.47M3.11M391K2.03M00000
Other Non-Cash Items
934K1.18M1.56M1.47M3.12M4.61M13.21M17.1M-2.96M-285K
Working Capital Changes
20.76M15.42M-7.26M-17.23M-31.14M10.61M13.48M-2.59M-10.19M-666K
Change in Receivables
-1.2M-2.52M1.07M-3.05M-12.12M1.82M-1.09M9.59M-8.06M-2.05M
Change in Inventory
-539K-2.07M-1.17M-1.08M29K-2.98M-1.93M4.42M-204K-513K
Change in Payables
2.63M2.16M1.4M751K-1.46M3.09M5.18M-8.92M4.55M1.73M
Cash from Investing
-5.16M-7.85M-81.58M-65.14M-60.07M52.54M13.1M-35.07M-22.57M-46.04M
Capital Expenditures
-5.16M-7.85M-8.38M-3.25M-11.08M-49.9M-10.91M-1.6M-4.5M-5.18M
CapEx % of Revenue
54.91%20.79%12.85%4.13%12.96%76.71%14.85%1.89%-8.04%
Acquisitions
0073.2M65.14M48.99M0-24.01M00120K
Investments
----------
Other Investing
00-73.2M-65.14M-48.99M024.01M242K00
Cash from Financing
16.4M-591K134.95M121.27M169.7M1.37M11.03M114.67M130.34M128.08M
Debt Issued (Net)
16.4M-645K-5M03.31M-1.1M174K-1.13M585K-5.1M
Equity Issued (Net)
00144.03M117.5M162.26M03.51M97.82M129.94M132.59M
Dividends Paid
0000000000
Share Repurchases
0000000000
Other Financing
2K54K-4.08M3.77M4.13M2.46M7.34M17.98M-189K589K
Net Change in Cash
11.54M▲ 0%
-2.87M▼ 124.9%
35.3M▲ 1328.8%
13.48M▼ 61.8%
38.85M▲ 188.2%
-16.46M▼ 142.4%
-32.14M▼ 95.3%
34.43M▲ 207.1%
32.83M▼ 4.6%
2.59M▲ 0%
Free Cash Flow
-4.87M▲ 0%
-2.28M▲ 53.2%
-26.45M▼ 1060.1%
-45.9M▼ 73.5%
-81.91M▼ 78.5%
-120.13M▼ 46.7%
-67.17M▲ 44.1%
-46.75M▲ 30.4%
-79.45M▼ 69.9%
-84.65M▲ 0%
FCF Margin %
-51.83%-6.04%-40.56%-58.36%-95.81%-184.68%-91.41%-55.25%--131.21%
FCF Growth %
-53.16%-1060.13%-73.52%-78.46%-46.66%44.09%30.39%-69.94%-81.23%
FCF per Share
-0.22-0.10-1.47-1.34-1.87-2.63-1.39-0.79-0.89-0.81
FCF Conversion (FCF/Net Income)
-0.01x-0.28x0.72x1.03x1.09x0.62x0.52x0.56x0.92x0.89x
Interest Paid
321K698K1.26M0000000
Taxes Paid
-5K-7K6K35K39K47K64K38K23K0

PSNL Key Ratios

Personalis, Inc. (PSNL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios

Metric20182019202020212022202320242025TTM
Return on Equity (ROE)
--16611.92%-27.37%-25.82%-42.89%-62.31%-48.91%-35.02%-43.52%
Return on Invested Capital (ROIC)
--31.34%-33.09%-24.48%-39.32%-55.37%-37.11%-40.69%-42.47%
Gross Margin
31.25%33.86%25.57%37.03%20.52%24.78%31.7%-13.72%
Net Margin
-52.64%-38.47%-52.49%-76.29%-174.2%-147.38%-96.06%--148.11%
Debt / Equity
-0.02x0.06x0.19x0.22x0.37x0.22x0.12x0.12x
Interest Coverage
-9.50x-21.13x-20610.50x-353.41x-562.56x-982.75x-3385.08x-395.34x-609.71x
FCF Conversion
-0.28x0.72x1.03x1.09x0.62x0.52x0.56x0.92x0.89x
Revenue Growth
302.15%72.62%20.61%8.7%-23.92%12.97%15.15%-100%-24.71%
Related:PSNL Dividend History·PSNL Revenue History·PSNL Price History·PSNL P/E History·PSNL Financial Ratios·PSNL Institutional Holders

PSNL SEC Filings & Documents

Personalis, Inc. (PSNL) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

May 13, 2026·SEC

Material company update

May 13, 2026·SEC

Material company update

May 7, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 26, 2026·SEC

FY 2025

Feb 27, 2025·SEC

FY 2024

Feb 28, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

May 7, 2026·SEC

FY 2025

Nov 4, 2025·SEC

FY 2025

Aug 5, 2025·SEC

PSNL Frequently Asked Questions

Personalis, Inc. (PSNL) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials

Personalis, Inc. (PSNL) reported $64.5M in revenue for fiscal year 2025. This represents a 587% increase from $9.4M in 2017.

Personalis, Inc. (PSNL) saw revenue decline by 100.0% over the past year.

Personalis, Inc. (PSNL) reported a net loss of $95.6M for fiscal year 2025.

Dividend & Returns

Personalis, Inc. (PSNL) has a return on equity (ROE) of -35.0%. Negative ROE indicates the company is unprofitable.

Personalis, Inc. (PSNL) had negative free cash flow of $84.6M in fiscal year 2025, likely due to heavy capital investments.

What if you invested $1,000 in PSNL back in 2017?

Total return calculator · dividends reinvested · 9+ years of data

See returns →

How much would $100/month in PSNL be worth today?

Dollar cost averaging calculator · DCA vs lump sum

Calculate →